Opus Genetics (IRD) Share-based Compensation (2010 - 2026)
Opus Genetics (IRD) reported Share-based Compensation of $1.5 million for Q1 2026, up 60.35% year-over-year from $913000.0 in Q1 2025, and up 157.98% quarter-over-quarter from -$2.5 million in Q4 2025.
Opus Genetics (IRD) Share-based Compensation (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $1.5 million, up 60.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $651000.0 (down 86.66% YoY), and the FY2025 annual result was $100000.0, down 97.03% from the prior year.
- Share-based Compensation climbed to $1.5 million in Q1 2026 per IRD's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $247.0 million in Q1 2023 and troughed at -$2.5 million in Q4 2025.
- A 5-year average of $16.0 million and a median of $758500.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 356.58% in 2022, then jumped 55405.62% in 2023.
- A 5-year view of Share-based Compensation shows it stood at -$1.2 million in 2022, then soared by 157.85% to $711000.0 in 2023, then soared by 344.73% to $3.2 million in 2024, then plunged by 179.85% to -$2.5 million in 2025, then jumped by 157.98% to $1.5 million in 2026.
- Business Quant data shows IRD's Share-based Compensation at $1.5 million in Q1 2026, -$2.5 million in Q4 2025, and $816000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Sep 30, 2025 | 816,000.00 |
| Sep 30, 2025 | 816,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Dec 31, 2024 | 3.16 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Jun 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 806,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 711,000.00 |
| Dec 31, 2023 | 711,000.00 |
| Sep 30, 2023 | 573,000.00 |
| Sep 30, 2023 | 573,000.00 |